• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

    3/6/24 4:05:55 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email
    SC 13G/A 1 d698453dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    CervoMed Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    15713L109

    (CUSIP Number)

    March 5, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of the section of the Act but shall be subject to all other provisions of that Act (however, see the Notes).

     

     

     


    CUSIP No. 15713L109

     

    1.   

    NAMES OF REPORTING PERSONS

     

    AI EIPP Holdings LLC

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐  (b) ☐

     

    3.   

    SEC USE ONLY:

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER:

     

    0

       6.   

    SHARED VOTING POWER:

     

    42,556(1)

       7.   

    SOLE DISPOSITIVE POWER:

     

    0

       8.   

    SHARED DISPOSITIVE POWER:

     

    42,556 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    42,556 (1)

    10.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.74%(2)

    12.   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    OO (Limited Liability Company)

     

    (1)

    Represents 42,556 shares of Common Stock underlying pre-funded warrants held by AI EIPP Holdings, LLC exercisable at a price per share of $19.81, on or before April 2, 2028 (the “Warrants”).

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    2


    CUSIP No. 15713L109

     

    1.   

    NAMES OF REPORTING PERSONS

     

    Access Industries Management, LLC

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐  (b) ☐

     

    3.   

    SEC USE ONLY:

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER:

     

    0

       6.   

    SHARED VOTING POWER:

     

    42,556 (1)

       7.   

    SOLE DISPOSITIVE POWER:

     

    0

       8.   

    SHARED DISPOSITIVE POWER:

     

    42,556 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    42,556 (1)

    10.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.74%(2)

    12.   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    OO (Limited Liability Company)

     

    (1)

    Represents 42,556 shares of Common Stock underlying the Warrants.

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2023.

     

    3


    CUSIP No. 15713L109

     

    1.   

    NAMES OF REPORTING PERSONS

     

    Len Blavatnik

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐  (b) ☐

     

    3.   

    SEC USE ONLY:

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER:

     

    0

       6.   

    SHARED VOTING POWER:

     

    42,556 (1)

       7.   

    SOLE DISPOSITIVE POWER:

     

    0

       8.   

    SHARED DISPOSITIVE POWER:

     

    42,556 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    42,556 (1)

    10.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.74%(2)

    12.   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    (1)

    Represents 42,556 shares of Common Stock underlying the Warrants.

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2023.

     

    4


    Schedule 13G

    CUSIP No. 15713L109

     

    Item 1.

     

      (a)

    Name of Issuer:

    CervoMed Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    20 Park Plaza, Suite 424

    Boston, Massachusetts 02216

     

    Item 2.

     

      (a)

    Name of Person Filing:

    This filing is being made on behalf of (collectively, the “Access Filers”):

    AI EIPP Holdings LLC (“AI EIPP”)

    Access Industries Management, LLC (“AIM”)

    Len Blavatnik

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.

     

      (c)

    Citizenship:

    Each of AI EIPP and AIM is a limited liability company organized under the laws of the State of Delaware.

    Mr. Blavatnik is a citizen of the United States of America.

     

      (d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    15713L109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

            (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e)    ☐    An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    5


    Not Applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.

     

      (b)

    Percent of class:

    See Item 11 of the attached cover pages. The percentages reported in Item 11 of the attached cover pages are based upon 5,674,520 shares of the Issuer’s Common Stock outstanding.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See the responses to Item 5 on the attached cover pages.

     

      (ii)

    Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     

      (iii)

    Sole power to dispose or to direct the disposition:

    See the responses to Item 7 on the attached cover pages.

     

      (iv)

    Shared power to dispose or to direct the disposition:

    See the responses to Item 8 on the attached cover pages.

    Warrants exercisable into 42,556 shares of Common Stock are deemed to be beneficially owned by AI EIPP pursuant to the terms of the warrant agreement. Such shares of Common Stock may be deemed to be beneficially owned by AIM and Mr. Blavatnik because (i) AIM is the sole manager of AI EIPP and (ii) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AI EIPP. Each of AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒: Each of the Access Filers ceased to beneficially own more than 5% of the shares of common stock of CervoMed Inc. on March 5, 2024. Consequently, this Amendment No. 2 constitutes an exit filing with respect to each of the Access Filers.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    6


    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

    7


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 6, 2024

     

    AI EIPP HOLDINGS LLC       By: Access Industries Management, LLC, its Manager
          /s/ Alejandro Moreno
          Name: Alejandro Moreno
          Title: Executive Vice President
    ACCESS INDUSTRIES MANAGEMENT, LLC       /s/ Alejandro Moreno
          Name: Alejandro Moreno
          Title: Executive Vice President
          *
          Name: Len Blavatnik

     

    *

    The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

        By:   /s/ Alejandro Moreno
        Name:   Alejandro Moreno
          Attorney-in-Fact

     

    8

    Get the next $CRVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    9/18/2024$55.00Buy
    Chardan Capital Markets
    More analyst ratings

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CervoMed upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

      3/13/25 7:28:49 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by H.C. Wainwright

      H.C. Wainwright downgraded CervoMed from Buy to Neutral

      12/17/24 7:40:50 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded CervoMed from Buy to Neutral

      12/11/24 7:28:58 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Financials

    Live finance-specific insights

    See more
    • CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

      A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

      3/10/25 4:05:00 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financia

      5/12/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

      BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 5:00 – 5:30 PM ETWebcast Link: https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website htt

      5/7/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

      During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD™ 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory The results demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB) BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage comp

      4/2/25 7:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    SEC Filings

    See more
    • SEC Form 424B5 filed by CervoMed Inc.

      424B5 - CervoMed Inc. (0001053691) (Filer)

      5/12/25 5:13:43 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CervoMed Inc. (0001053691) (Filer)

      5/12/25 4:29:50 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CervoMed Inc.

      10-Q - CervoMed Inc. (0001053691) (Filer)

      5/12/25 9:06:44 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gregoire Sylvie

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:02:31 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO & GC Elder William Robert

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:02:02 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Cobuzzi Robert Joseph Jr.

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:01:32 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

      4 - CervoMed Inc. (0001053691) (Issuer)

      8/27/24 4:09:50 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      11/14/24 3:09:10 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      4/11/24 7:55:23 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

      SC 13G/A - CervoMed Inc. (0001053691) (Subject)

      3/6/24 4:05:55 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    See more
    • CervoMed to Appoint William Elder as Chief Financial Officer

      BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

      5/20/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

      - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

      4/1/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

      Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

      2/7/24 8:30:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care